Quick Answer
Intellia Therapeutics, Inc. reported Total Assets of $842.13 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed a decrease of -29.3% in Total Assets from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $75.54 million | Q2 2016: $310.62 million | Q3 2016: $301.47 million | Q1 2017: $279.26 million | Q2 2017: $264.98 million | Q3 2017: $249.17 million | Q1 2018: $359.55 million | Q2 2018: $339.78 million | Q3 2018: $321.23 million | Q1 2019: $344.36 million | Q2 2019: $352.44 million | Q3 2019: $346.64 million | Q1 2020: $314.75 million | Q2 2020: $490.83 million | Q3 2020: $458.56 million | Q1 2021: $716.89 million | Q2 2021: $672.24 million | Q3 2021: $1.33 billion | Q1 2022: $1.20 billion | Q2 2022: $1.11 billion | Q3 2022: $1.08 billion | Q1 2023: $1.42 billion | Q2 2023: $1.32 billion | Q3 2023: $1.24 billion | Q1 2024: $1.26 billion | Q2 2024: $1.19 billion | Q3 2024: $1.17 billion | Q1 2025: $986.16 million | Q2 2025: $898.89 million | Q3 2025: $925.28 million.
- Over the full 11 years of available data (2015 to 2025), Intellia Therapeutics, Inc.'s Total Assets has grown by 925.2%.
- Historical annual values: Fiscal year 2025: $842.13 million | Fiscal year 2024: $1.19 billion | Fiscal year 2023: $1.30 billion | Fiscal year 2022: $1.52 billion | Fiscal year 2021: $1.29 billion | Fiscal year 2020: $676.32 million | Fiscal year 2019: $334.28 million | Fiscal year 2018: $347.32 million | Fiscal year 2017: $376.24 million | Fiscal year 2016: $298.97 million | Fiscal year 2015: $82.14 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: